Fenneke Zwierenga
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study.
Journal: The Lancet. Oncology
Published: October 15, 2025
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Journal: Targeted oncology
Published: May 07, 2025
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA.
Journal: ESMO open
Published: September 26, 2024
The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 14, 2024
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.
Journal: Cancer treatment reviews
Published: June 15, 2023
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 21, 2022
A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 24, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026